Yes, Symtuza Is a Single-Tablet Regimen for HIV
Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) is FDA-approved as a complete single-tablet regimen for HIV-1 treatment in adults and children weighing at least 35 kg. Patients take one tablet once daily with food, combining a protease inhibitor (darunavir), pharmacokinetic enhancer (cobicistat), and two nucleoside reverse transcriptase inhibitors (emtricitabine and tenofovir alafenamide).[1][2]
Who Can Use Symtuza?
It's indicated for treatment-naive or treatment-experienced adults without darunavir resistance, and virologically suppressed patients switching regimens. Not approved for those with known hypersensitivity to any component or creatinine clearance below 70 mL/min.[1][3]
How Does Symtuza Compare to Other Single-Tablet Regimens?
Symtuza stands out for boosted darunavir, which has a high barrier to resistance compared to integrase inhibitors in Biktarvy (bictegravir/FTC/TAF) or Dovato (dolutegravir/lamivudine). Phase 3 trials showed similar virologic suppression rates (91% vs. 93% for darunavir-based triple therapy) with fewer discontinuations due to side effects.[2][4]
| Regimen | Key Components | Common Use Case |
|---------|----------------|---------------|
| Symtuza | DRV/c/FTC/TAF | Resistance-prone patients |
| Biktarvy | BIC/FTC/TAF | First-line, broad use |
| Genvoya | EVG/c/FTC/TAF | Older integrase option |
What Side Effects Do Patients Report?
Common issues include diarrhea (6%), nausea (5%), and headache (4%), often mild. Kidney and bone risks from TAF are lower than older tenofovir formulations, but monitor lipids and liver function due to darunavir.[1][3] Rare cases of lactic acidosis or hepatotoxicity occur.
When Did Symtuza Launch and What's Its Patent Status?
Janssen launched Symtuza in the US in 2018. Key patents expire around 2031-2033, with challenges possible from generics; check DrugPatentWatch.com for updates on Paragraph IV filings or tentative approvals.[5]
[1]: Symtuza Prescribing Information, Janssen, 2023. https://www.symtuza.com
[2]: FDA Approval Letter, 2018. https://www.accessdata.fda.gov
[3]: ClinicalTrials.gov, AMBER and EMERALD studies.
[4]: Orkin et al., Lancet, 2018.
[5]: DrugPatentWatch.com, Symtuza patents. https://www.drugpatentwatch.com/p/tradename/SYMTUZA